AstraZeneca plc (LON:AZN) has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to..

AstraZeneca plc (LON:AZN) COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. The three approvals authorise Lynparza for: maintenance treatment after 1st-line..

AstraZeneca plc (LON:AZN)’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union for an additional dosing option, 1,500mg fixed dose every four weeks, in the approved indication..

AstraZeneca plc (LON:AZN) has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal GmbH (Grünenthal)...

AstraZeneca plc (LON:AZN) has announced that positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in..

AstraZeneca plc (LON:AZN) Imfinzi has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III..

AstraZeneca plc (LON:AZN) Brilinta has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and..

AstraZeneca plc (LON:AZN) has announced that with effect from 1 November 2020, Diana Layfield is appointed as a Non-Executive Director. Diana Layfield is President, EMEA Partnerships at Google, driving technology..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo Company Limited’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application and has also been granted Priority Review in the US..

AstraZeneca plc (LON:AZN) Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application and has also been granted Priority Review in the US for the adjuvant treatment of patients with..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with..

AstraZeneca plc (LON:AZN) long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are..

AstraZeneca’s Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic kidney disease (CKD), with and without type-2 diabetes (T2D). CKD is a serious, progressive condition..

AstraZeneca PLC (LON:AZN) has announced that with effect from 1 October 2020, Dr Euan Ashley is appointed as a Non-Executive Director and a member of the Science Committee. Euan Ashley..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient..